Growth Metrics

Adma Biologics (ADMA) Non-Current Debt (2016 - 2025)

Adma Biologics (ADMA) has disclosed Non-Current Debt for 12 consecutive years, with $69.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt fell 4.16% year-over-year to $69.3 million, compared with a TTM value of $69.3 million through Dec 2025, down 4.16%, and an annual FY2025 reading of $69.3 million, down 4.16% over the prior year.
  • Non-Current Debt was $69.3 million for Q4 2025 at Adma Biologics, down from $70.1 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $144.3 million in Q1 2023 and bottomed at $69.3 million in Q4 2025.
  • Average Non-Current Debt over 5 years is $110.9 million, with a median of $116.0 million recorded in 2023.
  • The sharpest move saw Non-Current Debt skyrocketed 531.83% in 2021, then tumbled 44.61% in 2024.
  • Year by year, Non-Current Debt stood at $94.9 million in 2021, then soared by 50.56% to $142.8 million in 2022, then dropped by 8.57% to $130.6 million in 2023, then crashed by 44.61% to $72.3 million in 2024, then decreased by 4.16% to $69.3 million in 2025.
  • Business Quant data shows Non-Current Debt for ADMA at $69.3 million in Q4 2025, $70.1 million in Q3 2025, and $73.4 million in Q2 2025.